Bicycle Therapeutics plc American Depositary Receipt

Bicycle Therapeutics plc is a biopharmaceutical company developing precision-guided therapeutics to treat solid tumors. The company specializes in bicyclic peptides, a novel class of fully synthetic, chemically-derived medicines formed by constraining short linear peptides into a stabilized bi-cyclic structure. These molecules are designed to penetrate deep into tissues and target intractable cancers by engaging targets historically challenging for conventional non-biological therapeutic approaches. Bicycle's proprietary technology platform enables the creation of versatile drug candidates with high affinity and selectivity. The company maintains a transatlantic presence, headquartered in Cambridge, United Kingdom, with operations in Boston, Massachusetts. Bicycle has multiple molecules in clinical development and additional discovery-stage projects advancing through its pipeline, reflecting its commitment to becoming one of the world's leading solid tumor therapeutics companies and expanding treatment options for patients with high therapeutic needs.